Pre-made Felzartamab benchmark antibody ( Whole mAb, anti-CD38 therapeutic antibody, Anti-ADPRC1/ADPRC 1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Felzartamab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38. ... The drug is currently in phase 3 of clinical trials for the treatment of multiple myeloma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-208-1mg	1mg	3090
GMP-Bios-ab-208-10mg	10mg	Inquiry
GMP-Bios-ab-208-100mg	100mg	Inquiry
GMP-Bios-ab-208-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Felzartamab biosimilar, Whole mAb, Anti-CD38 Antibody: Anti-ADPRC1/ADPRC 1 therapeutic antibody
INN Name	Felzartamab
Target	CD38
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	MorphoSys
Conditions Approved	na
Conditions Active	Multiple myeloma;Membranous glomerulonephritis;Leukemia;Systemic lupus erythematosus
Conditions Discontinued	Non-small cell lung cancer
Development Tech	na